Therefore, by using our unique PDX models, we were able to perform longitudinal study and view the dynamic regulation of B7-H3 expression following ADT: B7-H3 expression rises during the early stage of ADT treatment (AR regulation is dominant), gradually drops and reaches its lowest level during ADT-induced tumor dormancy and gradually increases at relapse (proliferation-related regulation is dominant). Here, CD276 is linked to neoplasm.